EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 61999TJ0326
Judgment of the Court of First Instance (Fifth Chamber) of 18 December 2003.#Nancy Fern Olivieri v Commission of the European Communities and European Agency for the Evaluation of Medicinal Products.#Medicinal product - Marketing authorisation - Opinion of the European Agency for the Evaluation of Medicinal Products - Admissibility - Interest in bringing proceedings - Public health - Verification of reported data - Review of scientific evaluations - Professional reputation.#Case T-326/99.
Sodba Sodišča prve stopnje (peti senat) z dne 18. decembra 2003.
Nancy Fern Olivieri proti Komisiji Evropskih skupnosti in Evropski agenciji za vrednotenje zdravil.
Dopustnost.
Zadeva T-326/99.
Sodba Sodišča prve stopnje (peti senat) z dne 18. decembra 2003.
Nancy Fern Olivieri proti Komisiji Evropskih skupnosti in Evropski agenciji za vrednotenje zdravil.
Dopustnost.
Zadeva T-326/99.
ECLI identifier: ECLI:EU:T:2003:351
«(Medicinal product – Marketing authorisation – Opinion of the European Agency for the Evaluation of Medicinal Products – Admissibility – Interest in bringing proceedings – Public health – Verification of reported data – Review of scientific evaluations – Professional reputation)»
|
||||
(Art. 230, fourth para., EC)
(Art. 152 EC; Council Regulation No 2309/93, Art. 11)
(Council Regulation No 2309/93)
(Council Regulation No 2309/93, Art. 68)
JUDGMENT OF THE COURT OF FIRST INSTANCE (Fifth Chamber)
18 December 2003 (1)
((Medicinal product – Marketing authorisation – Opinion of the European Agency for the Evaluation of Medicinal Products – Admissibility – Interest in bringing proceedings – Public health – Verification of reported data – Review of scientific evaluations – Professional reputation))
In Case T-326/99, Nancy Fern Olivieri, resident in Toronto (Canada), represented by N. Green QC and J. Marks, barrister, and R. Stein, solicitor, with an address for service in Luxembourg,applicant,
v
Commission of the European Communities, andEuropean Agency for the Evaluation of Medicinal Products, represented by R. Wainwright and H. Støvlbæk, acting as Agents, with an address for service in Luxembourg,defendants,
supported byApotex Europe Ltd, established in Leeds (United Kingdom), represented by P. Bogaert and G. Berrisch, lawyers, and G. Castle, solicitor, with an address for service in Luxembourg,intervener,
APPLICATION for annulment of the Commission Decision of 25 August 1999 granting marketing authorisation for the medicinal product for human use known as Ferriprox-Deferiprone [C(1999) 2820] and of the revised Opinion of the European Agency for the Evaluation of Medicinal Products of 23 June 1999,THE COURT OF FIRST INSTANCE OF THE EUROPEAN COMMUNITIES (Fifth Chamber),
having regard to the written procedure and further to the hearing on 10 April 2003,
gives the following
On those grounds,
THE COURT OF FIRST INSTANCE (Fifth Chamber)
hereby:
García-Valdecasas |
Lindh |
Cooke |
H. Jung |
P. Lindh |
Registrar |
President |